About amgen inc. - AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.
AMGN At a Glance
Amgen, Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
| Phone | 1-805-447-1000 | Revenue | 28.01B | |
| Industry | Biotechnology | Net Income | 6.72B | |
| Sector | Health Technology | 2023 Sales Growth | 7.351% | |
| Fiscal Year-end | 12 / 2024 | Employees | 26,700 | |
| View SEC Filings |
AMGN Valuation
| P/E Current | 35.693 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.069 |
| Price to Sales Ratio | 5.532 |
| Price to Book Ratio | 24.744 |
| Price to Cash Flow Ratio | 18.292 |
| Enterprise Value to EBITDA | 16.95 |
| Enterprise Value to Sales | 7.477 |
| Total Debt to Enterprise Value | 0.312 |
AMGN Efficiency
| Revenue/Employee | 1,049,063.67 |
| Income Per Employee | 251,573.034 |
| Receivables Turnover | 3.527 |
| Total Asset Turnover | 0.345 |
AMGN Liquidity
| Current Ratio | 1.649 |
| Quick Ratio | 1.132 |
| Cash Ratio | 0.595 |
AMGN Profitability
| Gross Margin | 69.957 |
| Operating Margin | 30.243 |
| Pretax Margin | 28.044 |
| Net Margin | 23.981 |
| Return on Assets | 8.279 |
| Return on Equity | 135.793 |
| Return on Total Capital | 9.374 |
| Return on Invested Capital | 12.033 |
AMGN Capital Structure
| Total Debt to Total Equity | 1,049.791 |
| Total Debt to Total Capital | 91.303 |
| Total Debt to Total Assets | 67.339 |
| Long-Term Debt to Equity | 1,024.727 |
| Long-Term Debt to Total Capital | 89.123 |
Amgen Inc. in the News
FTC sues to stop Amgen’s $27.8B deal for Horizon Therapeutics
The FTC said in its complaint that Amgen would be able to leverage its position with insurance companies and pharmacy benefit managers wanting access to its blockbuster drugs.
Biden pushes Congress to allow Medicare to negotiate drug prices
President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.